GlassScriptPhysician profile
Megan P Caroway
NPI 1255726550
$3,614.95
in general payments reported to CMS, 2019-2025
33 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $19.57 · 2021: $160 · 2022: $690 · 2023: $1,191 · 2024: $626 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $486.88 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $390.18 | 2021-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $296.37 | 2022-2025 | Terlivaz |
| Vifor Pharma, INC. | $260.11 | 2021-2025 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $256.71 | 2021-2025 | Lupkynis |
| Amgen INC. | $201.21 | 2020-2024 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $186.19 | 2022-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $139.61 | 2019-2025 | Farxiga |
| Abbott Laboratories | $127.87 | 2022-2023 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $116.59 | 2023-2025 | |
| Baxter Healthcare | $115.00 | 2019 | |
| Calliditas Therapeutics US INC. | $114.47 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $102.52 | 2024-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $94.97 | 2021-2025 | Givlaari, Oxlumo |
| Daiichi Sankyo INC. | $93.18 | 2022-2024 | Injectafer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $75.84 | 2022-2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.05 | 2023-2024 | Jardiance |
| Travere Therapeutics, INC. | $53.23 | 2023-2025 | |
| Eurofins Viracor, LLC | $51.17 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $49.42 | 2023-2024 | Crysvita |
| Horizon Therapeutics Plc | $46.78 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $41.77 | 2021-2023 | Rayaldee |
| Ani Pharmaceuticals, INC. | $35.78 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.33 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $25.20 | 2025 | |
| Lilly USA, LLC | $24.03 | 2023 | Jardiance |
| Alexion Pharmaceuticals, INC. | $21.67 | 2025 | Ultomiris |
| Akebia Therapeutics INC | $21.64 | 2023 | Auryxia |
| Cycle Pharmaceuticals INC | $21.51 | 2025 | Venxxiva |
| Nxstage Medical, INC. | $20.74 | 2025 | Liberty Select Cycler, Nxstage System One, Pureflow Sl |
| Novo Nordisk INC | $18.20 | 2023 | Ozempic |
| Pharmacosmos Therapeutics INC. | $15.62 | 2021 | |
| Renalytix Ai, INC. | $15.11 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Caroway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.